December 2020: We have amended recommendations 1.7.17 and 1.7.20 to bring them in line with the diabetic eye screening programme. The evidence for these recommendations has not been reviewed, and they are marked [2009, amended 2020].
August 2019: The recommendations in section 1.4 on diagnosing and managing hypertension have been removed because diagnosis, treatment and monitoring of hypertension is broadly the same for people with type 2 diabetes as for other people (see the NICE guideline on hypertension in adults). When a different approach is needed for people with type 2 diabetes, this is specified in the hypertension guideline.
May 2017: Text on sodium–glucose cotransporter 2 (SGLT2) inhibitors was added to the section on initial drug treatment. The algorithm for blood glucose lowering therapy in adults with type 2 diabetes was also updated to revise footnote b with links to relevant NICE guidance on SGLT2 inhibitors, and new information on SGLT2 inhibitors was also added to the box on action to take if metformin is contraindicated or not tolerated.
December 2016: The text after recommendation 1.6.31 and the algorithm for blood glucose lowering therapy were updated to refer to NICE technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes (TA418).
December 2015: We updated and replaced NICE guideline CG87 (published May 2009) and NICE technology appraisal guidance 203 and 248.
Recommendations are marked as ,  or [2009, amended 2015]:
 indicates that the evidence has been reviewed.
 indicates that the evidence has not been reviewed since 2009.
[2009, amended 2015] or [2009, amended 2016] indicates that the evidence has not been reviewed since 2009, but either changes have been made to the recommendation wording that change the meaning or NICE has made editorial changes to the original wording to clarify the action to be taken (see below).
We have made a change without an evidence review:
The recommendation on the treatment of gastroparesis was replaced by recommendations from the NICE guideline on type 1 diabetes.
This change is labelled .
Minor changes since publication
December 2019: Relationships to the NICE guideline on hypertension were clarified, and a link was added to the decision aid on choice of medicine to control blood glucose. We added a link to the patient decision aid and user guide about taking a second medicine to control blood glucose.
June 2018: Recommendation 1.3.11 was added to provide a link to NICE's advice on bariatric surgery.
January 2018: Notes were added with links to MHRA warnings about sodium–glucose cotransporter 2 (SGLT2) inhibitors.